NASDAQ listed innovative biotherapeutic company ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) could be the stock to watch today and especially after a major development that took place towards the end of February. Back on February 27, 2022, it emerged that existing institutional investors in the company Marshall Wace LLP had decided to grow their stake in ImmunoPrecise.
Key Details
When an existing investor raises his stake considerably then it is an indication of the fact that it is confident about the company’s future and hence, it is an important development. As per the disclosures made with the United States Securities and Exchange Commission, Marshall Wace raised its stake in the company but a staggering 384.1%.
During the course of the third quarter, the firm bought as many as 139255 shares in the company in the third fiscal quarter and took its holding to 175514. That took the total stake owned by Marshall Wace in ImmunoPrecise to as much as 0.91%.
The investors spent as much as $1092000 in order to purchase the shares as per the filings with the United States Securities and Exchanges Commission. In addition to that, it is perhaps also pertinent to point out that in recent times some other hedge funds have also transacted in the shares of the company.
Considering the fact that the stock has managed to garner such interest from institutions, it may be a good time for investors to perhaps start taking a keener interest in ImmunoPrecise. It should be noted that at this point in time the company is best known for offering a wide range of services and programs to its clients and customers.
Most of those programs are also equipped with advanced technologies and platforms. It is offered to businesses and scientists in order to promote the task of discovering antibodies. It may be the right time to add the stock to your watch lists.
